Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Pauline Finlay"'
Autor:
Julia M.W. Gee, Andrew Foxley, Pauline Finlay, Rahul Deb, Gaia Schiavon, Paul Rugman, Martin Pass, Justin P.O. Lindemann, Loumpiana Koulai, Elza C. de Bruin, Marie Cullberg, S.Y. Amy Cheung, Roberta Littleford, Petra Rauchhaus, Kieran Horgan, Ali Jahan, Samreen Ahmed, Daniel Rea, Anthony Skene, Chris Holcombe, Abigail Evans, Kwok-Leung Cheung, Robert E. Coleman, John F.R. Robertson
Purpose:The STAKT study examined short-term exposure (4.5 days) to the oral selective pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its therapeutic target in sufficient concentration to significantly modulate key biomar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36ce4aaa6b32841a0165d4e23b5bbbdf
https://doi.org/10.1158/1078-0432.c.6530157.v1
https://doi.org/10.1158/1078-0432.c.6530157.v1
Autor:
Julia M.W. Gee, Andrew Foxley, Pauline Finlay, Rahul Deb, Gaia Schiavon, Paul Rugman, Martin Pass, Justin P.O. Lindemann, Loumpiana Koulai, Elza C. de Bruin, Marie Cullberg, S.Y. Amy Cheung, Roberta Littleford, Petra Rauchhaus, Kieran Horgan, Ali Jahan, Samreen Ahmed, Daniel Rea, Anthony Skene, Chris Holcombe, Abigail Evans, Kwok-Leung Cheung, Robert E. Coleman, John F.R. Robertson
Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23e07284ffe3c87c709eb8b178322f8c
https://doi.org/10.1158/1078-0432.22479243.v1
https://doi.org/10.1158/1078-0432.22479243.v1
Autor:
Sandra E. Dunn, Michael Pollak, Marco Gottardis, Joan Carboni, Robert I. Nicholson, Helen E. Jones, Pauline Finlay, Julia M.W. Gee, Eugene Park, Anna L. Stratford, Michelle Y.C. Wang, Hamid Masoudi, Kaiji Hu, Golareh Habibi, Jennifer H. Law
Supplementary Figure 1 from Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ed96153bfbcc226a63b1ca283392dc9
https://doi.org/10.1158/0008-5472.22375809.v1
https://doi.org/10.1158/0008-5472.22375809.v1
Autor:
John F.R. Robertson, Robert E. Coleman, Kwok-Leung Cheung, Abigail Evans, Chris Holcombe, Anthony Skene, Daniel Rea, Samreen Ahmed, Ali Jahan, Kieran Horgan, Petra Rauchhaus, Roberta Littleford, S.Y. Amy Cheung, Marie Cullberg, Elza C. de Bruin, Loumpiana Koulai, Justin P.O. Lindemann, Martin Pass, Paul Rugman, Gaia Schiavon, Rahul Deb, Pauline Finlay, Andrew Foxley, Julia M.W. Gee
Publikováno v:
Clinical Cancer Research. 28:5469-5469
Autor:
Marie Cullberg, Andrew Foxley, Martin Pass, E. De Bruin, Kieran Horgan, L Koulai, Daniel Rea, R. Deb, Roberta Littleford, A Cheung, Anthony Skene, Paul Rugman, J Gee, Robert E. Coleman, Andrew Evans, Gaia Schiavon, K.L. Cheung, J.F.R. Robertson, Samreen Ahmed, Pauline Finlay, Petra Rauchhaus, A Jahan, Christopher Holcombe
Publikováno v:
Cancer Research. 79:P2-12
Background: Capivasertib (AZD5363), an AKT1,2,3 inhibitor, significantly improved progression-free and overall survival when added to paclitaxel in triple negative breast cancer (BC) patients (Schmid et al. ASCO 2018). We have previously reported in
Autor:
John F.R. Robertson, Christine M. Pierce Campbell, Andrew R. Green, Ian Bradbury, Signe Borgquist, Julia Margaret Wendy Gee, John Mathew, Ian O. Ellis, Karin Elebro, Pauline Finlay
Background: It remains clinically important to identify ER positive breast cancers likely to respond to tamoxifen (TAM) and so we aimed to select a group of biomarkers able to predict response. We also assessed whether data from different sample type
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9096df0a828ca1014d154a0bf9abd41
Autor:
A Jahan, S.Y. Amy Cheung, Andrew Foxley, John F.R. Robertson, Petra Rauchhaus, Gaia Schiavon, Julia Margaret Wendy Gee, Elza C. de Bruin, Samreen Ahmed, Kieran Horgan, Loumpiana Koulai, Kwok-Leung Cheung, Robert E. Coleman, Chris Holcombe, Roberta Littleford, Marie Cullberg, Anthony Skene, R. Deb, Justin P.O. Lindemann, Paul Rugman, Pauline Finlay, Abigail Evans, Daniel Rea, Martin Pass
Purpose: The STAKT study examined short-term exposure (4.5 days) to the oral selective pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its therapeutic target in sufficient concentration to significantly modulate key bioma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5cb3f09fdd862004c3d154d28b0c467
https://eprints.whiterose.ac.uk/159608/1/1078-0432.CCR-19-3053.full.pdf
https://eprints.whiterose.ac.uk/159608/1/1078-0432.CCR-19-3053.full.pdf
Autor:
John F R, Robertson, Robert E, Coleman, Kwok-Leung, Cheung, Abigail, Evans, Chris, Holcombe, Anthony, Skene, Daniel, Rea, Samreen, Ahmed, Ali, Jahan, Kieran, Horgan, Petra, Rauchhaus, Roberta, Littleford, S Y Amy, Cheung, Marie, Cullberg, Elza C, de Bruin, Loumpiana, Koulai, Justin P O, Lindemann, Martin, Pass, Paul, Rugman, Gaia, Schiavon, Rahul, Deb, Pauline, Finlay, Andrew, Foxley, Julia M W, Gee
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(7)
The STAKT study examined short-term exposure (4.5 days) to the oral selective pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its therapeutic target in sufficient concentration to significantly modulate key biomarkers of
Autor:
Silvia, Ziliotto, Julia M W, Gee, Ian O, Ellis, Andrew R, Green, Pauline, Finlay, Anna, Gobbato, Kathryn M, Taylor
Publikováno v:
Metallomics
Zinc transporter ZIP7 activates key downstream signalling pathways and is correlated with important clinicopathological parameters that are associated with endocrine resistance.
ZIP7, a member of the ZIP family of zinc importers, resides on the
ZIP7, a member of the ZIP family of zinc importers, resides on the
Autor:
J Gee, A Haegebarth, Pauline Finlay, J Mathew, Ian Bradbury, Signe Borgquist, O Politz, Ian O. Ellis, J.F.R. Robertson, K Elebro, Christine M. Pierce Campbell, Andrew R. Green
Publikováno v:
Cancer Research. 79:P2-03
Aim: To select tumor biomarkers, included in the AKT pathway, able to predict response to tamoxifen (TAM) in patients with estrogen receptor (ER) positive breast cancer. Patients & Methods: 157 endocrine treatment naïve patients with known ER and HE